The Recent Curative Effect Observationof Antiviral Therapy For Hepatitis B Virus-associated Hepatocellular Carcinoma After TACE

ObjectivesThis observation of the changes in HBV-related liver cancer patients aboutclinical indicators pro and after antiviral therapy，And make an objective evaluationabout recent antiviral effect on HBV-related liver cancer treatment.MethodsA retrospective analysis method was used,which collected127HBV associatedliver cancer patients of the Second Affiliated Hospital of Zhengzhou University fromJune2010to December2012,105men, and22women, and all of them were atadvanced stage and serum HBsAg, HBV DNA, AFP positive.68of which did notreceive any interferon and nucleoside analogues (acid) treatment previously, andcombined with no other types of hepatitis.68patients were treated with(Transcatheter arterial chemoembolization)TACE finally, then divided into researchand control group according to weather received nucleoside analogs treatment(patients signed informed consent and the treatment was agreed by the hospital ethicscommittee). The research group were45cases, male: female=40:5and receivedlamivudine antiviral treatment0.1g/day; Control group23cases, male: female= 19:4，who were treated with TACE only. The follow-up period was October1,2013.Compared the serum HBV DNA overcast rate, liver function, Child-Pugh grading,serum levels of tumor markers and imaging examination results of the two groups, at0(that is, the preoperative), January, march, June, respectively. Using SPSS17.0software to do statistical analysis, a=0.05.ResultsData obtained were observed: Review the ALT levels of research group weresignificantly lower than those in the control group at the first, third,6thmonths(P<0.05).The levels of AST, GGT, Child-Pugh, AFP, CA199of the researchgroup were significantly decreased than those in the control group at the third,6thmonths (P <0.05)；Levels of serum HBV DNA negative rate was significantlydifferent between the two groups at the first month after antiviral therapy, with theprolonged treatment time, The HBV DNA negative rate of the research groupgradually increased.60%patients in research group had HBV DNA negative rate atthe6thmonth, But HBV DNA negative rate had only4%of the control group.ConclusionsClinical experience had demonstrated nucleoside (acid) representative drugLAM can quickly and potently inhibit the replication of HBV, improve and stabilizeliver function, reduce Child-Pugh score, and slow disease progression. It is theconclusion that HBV-related hepatocellular carcinoma after TACE treatment derivedantiviral treatment.